Ceftriaxone plus once daily aminoglycoside with filgrastim for treatment of febrile neutropenia: Early hospital discharge vs. standard in-patient care

Chemotherapy

Volumn 45, Issue 6, 1999, Pages 466-476

  Rapoport, B L ^a,i   Sussmann, O ^b   Herrera, M V ^b   Schlaeffer, F ^c   Otero, J C ^d   Pavlovsky, S ^e   Iglesias, L ^f   Stein, G ^g   Charnas, R ^h   Heitlinger, E ^h   Handschin, J ^h  

^a Medical Oncology Center of Rosebank   (South Africa)

^b Instituto Nacional de Cancerología   (Colombia)

^c BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^d INSTITUTO NACIONAL DE ENFERMEDADES NEOPLÁSICAS   (Peru)

^e Fundacion para Combatir La Leucemia   (Argentina)

^f HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^g Statistics for Research SFR Ltd   (Switzerland)

^h F HOFFMANN LA ROCHE LTD   (Switzerland)

ⁱ NONE   (South Africa)

Author keywords

Aminoglycoside; Ceftriaxone; Duration of hospitalization; Febrile neutropenia; Filgrastim; In patient vs. out patient

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; CEFTRIAXONE; GENTAMICIN; NETILMICIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG FATALITY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; FEVER; FOLLOW UP; HOSPITAL CARE; HOSPITAL DISCHARGE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUTROPHIL; OUTPATIENT CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; AGED; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; CEFTRIAXONE; FEMALE; FEVER; FILGRASTIM; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; NEUTROPENIA;

EID: 0032737621     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000007240     Document Type: Article

References (43)

1. Pizzo PA: Drug therapy: Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 1993;328:1323-1332.
2. Klastersky J: Science and pragmatism in the treatment and prevention of neutropenic infection. J Antimicrob Chemother 1998;41 (suppl D): 13-24.
3. Carratala J, Karthaus M: Evolution towards community treatment of neutropenic patients. Int J CHn Pract 1998;suppl 95:5-6.
4. Freifeld AG, Pizzo PA: The outpatient management of febrile neutropenia in cancer patients. Oncology 1996;10:599-616.
5. Rubenstein EB, Rolston K: Outpatient management of febrile episodes in neutropenic cancer patients. Support Care Cancer 1994;2: 369-373.
6. Talcott JA: Outpatient management of febrile neutropenia: Should we change the standard of care? Oncologist 1997;2:365-373.
7. Mayordomo JI, Rivera F, DiazPuente T, Lianes P, Colomer R, Lopez-Brea M, Lopez E, Paz-Ares L, Hitt R, Garcia-Ribas I, Cubedo R, Alonso S, Cortes-Funes H: Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors. J Natl Cancer Inst 1995;87: 803-808.
8. Maher DW, Lieschke DJ, Green M, Bishop J, Stuart-Harris R, Wolf M, Sheridan WP, Kefford RF, Cebon J, Olver J: Filgrastim in patients with chemotherapy-induced febrile neutropenia: A double-blind, placebocontrolled trial. Ann Intern Med 1994;121:492-501.
9. Venditti M, Martino P, Viscoli C, Klastersky J: Ceftriaxone alone or in combination with antibiotics in the management of infection in cancer patients. A review of 41 clinical trials involving 7,350 patient episodes. Clin Drug Invest 1999;17: 195-210.
10. Karthaus M, Egerer G, Kullmann K-H, Ritter J, Jürgens H: Ceftriaxone in the outpatient treatment of cancer patients with fever and neutropenia. Eur J Clin Microbiol Infect Dis 1998;17:501-504.
11. Martino P, Girmenia C, Raccah R, Micozzi A, Cimino G, Sgadari C, Gentile G: Single daily dose ceftriaxone plus amikacin treatment of febrile episodes in neutropenic patients attending day hospital for hematologic malignancies. Oncology 1992;49:49-52.
12. Sahu S, Bapna A, Pai SK, Nair CN, Kurkure PA, Advani SH: Outpatient antibacterial protocol for febrile neutropenia: A nonrandomized prospective trial using ceftriaxone, amikacin, and oral adjuvant agents. Pediatr Hematol Oncol 1997;14:205-211.
13. Khaliq Y, Bence-Bruckler I, Bredeson C, van-der-Jagt R, McDiarmid S, Huebsch LB: Once daily ceftriaxone for febrile neutropenia in an outpatient blood and marrow transplant programme. Blood 1995;86 (suppl 1):212A.
14. Mustafa MM, Aquino VM, Pappo A, Tkaczewski I, Buchanan GR: A pilot study of outpatient management of febrile neutropenic children with cancer at low risk of bacteremia. J Pediatr 1996;128:847-849.
15. Preis S, Juergens H, Friedland C, Oudekotte-David AA, Thomas L, Goebel U: Ceftriaxone alone or in combination with teicoplanin in the management of febrile episodes in neutropenic children and adolescents with cancer on an outpatient basis. Klin Pädiatr 1993;205:295-299.
16. Girmenia C, Moleti ML, Cartoni C, Cedrone M, De Gregoris C, De Sanctis V, Giovannini M, Latagliata R, Niscola P, Romani C, Rondinelli MB, Tosti S, Mandelli F: Management of infective complications in patients with advanced hematologic malignancies in home care. Leukemia 1997;11:1807-1812.
17. Kaplinsky C, Drucker M, Goshen J, Tamary H, Cohen IJ, Zaizov R: Ambulatory treatment with ceftriaxone in febrile neutropenic children. Isr J Med Sci 1994;30:649-651.
18. Pizzo PA, Armstrong D, Bodey GP, de Pauw B, Feld R, Glauser MP, Gaya H, Karp J, Klastersky J, Todeschini G, Verhoef J, Wade J, Young LS, Remington J, the Immunocompromised Host Society: The design, analysis and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient. J Infect Dis 1990;161: 397-401.
19. International Reporting of Periodic Drug-Safety Update Summaries: Final Report of the Council for International Organization of Medical Sciences (CIOMS) Working Group II. Geneva, CIOMS, 1992.
20. SAS® Statistics users guide version 6, ed 4. Cary, SAS Institute, 1991.
21. Malik I, Khan WA, Karim M, Aziz Z, Ata Khan M: Feasibility of outpatient management of fever in cancer patients with low-risk neutropenia: Results of a prospective randomized trial. Am J Med 1995;98:224-231.
22. Calandra T, Zinner S, Viscoli C, De Bock R, Gaya H, Neunier F, Klastersky J, Glauser M: Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia (EORTC-IATCG trial VIII). Ann Intern Med 1993;119:584-593.
23. Charnas R, Ridolfi Lüthi A, Ruch W: Writing committee for the international collaboration on antimicrobial treatment of febrile neutropenia in children. Once daily ceftriaxone plus amikacin vs. three times daily ceftazidime plus amikacin for treatment of febrile neutropenic children with cancer. Pediatr Infect Dis J 1997;16:346-353.
24. Pession A, Prete A, Paolucci G: Cost-effectiveness of ceftriaxone and amikacin as single daily dose for the empirical management of febrile granulocytopenic children with cancer. Chemotherapy 1997;43:358-366.
25. Bodey GP, Buckley M, Sathe YS, Freireich EJ: Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966;64: 328-340.
26. Talcott JA, Finberg R, Mayer RJ, Goldmann L: The medical course of cancer patients with fever and neutropenia. Arch Intern Med 1988; 148:2561-2568.
27. Talcott JA, Whalen A, Clark J: Home antibiotic therapy for low-risk cancer patients with fever and neutropenia: A pilot study of 30 patients based on a validated prediction rule. J Clin Oncol 1994;12:107-114.
28. American Society of Clinical Oncology: American Society of Clinical Oncology recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines. Clin Oncol 1994;12:2471-2508.
29. American Society of Clinical Oncology: Update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines. Clin Oncol 1996;14:1957-1960.
30. Varthalitis I, Athanassiou A, Mylonakis A, Tsielepsis M, Pectasidis D, Afaras G, Dimitriadis M: Ceftriaxone plus gentamycin and G-CSF, versus ciprofloxacin, gentamycin and G-CSF, in febrile neutropenic patients with chemotherapy-induced neutropenia. Eur J Cancer 1995;31(suppl 5):S261.
31. Weide R, Ikan N, Muller HH, Faber E, Wolf M, Simon C, Ecker T, Vogel F, Lode H: Randomized trial comparing ceftazidime vs. ceftriaxone in severe febrile neutropenia. Antiinfect Drugs Chemother 1998;16: 189-194.
32. Karthaus M, Wolf HH, Egerer G, Kämpfe D, Suedhoff T, Ritter J, Jürgens H: Ceftriaxone in the treatment of solid tumor patients with febrile neutropenia. Onkologie 1998;21:212-216.
33. Rossini F, Pioltelli P, Bolis S, Borin L, Casaroli I, Lanzi E, Maffe P, Parma M, Tripputi P, Pogliani EM: Ceftriaxone/amikacin vs. ceftazidime/amikacin as empirical therapy for fever in patients with haematological malignancy and severe granulocytopenia. Clin Drug Invest 1998:15:425-433.
34. Johannson PJH, Sternby E, Ursing B: Septicemia in granulocytopenic patients: A shift in bacterial etiology. Scand J Infect Dis 1992;24:357-360.
35. Langley J, Gold R: Sepsis in neutropenic children with cancer. Pediatr Infect Dis J 1988;7:34-37.
36. Oppenheim BA: The changing pattern of infection in neutropenic patients. J Antimicrob Chemother 1998;41(suppl D):7-11.
37. Gerberding JL: Aminoglycoside dosing: Timing is of the essence. Am J Med 1998;105:256-258.
38. Preston SL, Briceland LL: Single daily dosing of aminoglycosides. Pharmacotherapy 1995;15:297-316.
39. Bailey TC, Little JR, Littenberg B, Reichley RM, Dunagan WC: A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis 1997;24:786-795.
40. Hatala R, Dinh TT, Cook DJ: Single daily dosing of aminoglycosides in immunocompromised adults: Asystematic review. Clin Infect Dis 1997;24:810-816.
41. Karthaus M, Wolf HH, Kämpfe D, Egerer G, Ritter J, Peters G, Südhoff T, Franke A, Heil G, Kullmann KH, Jürgens H: Ceftriaxone monotherapy in the treatment of low-risk febrile neutropenia. Chemotherapy 1998;44:343-354.
42. Talcott JA, Siegel RD, Finberg R, Goldman L: Risk assessment in cancer patients with fever and neutropenia: A prospective, two-center validation of a prediction rule. Clin Oncol 1992;10:316-322.
43. Viscoli C: The evolution of the empirical management of fever and neutropenia in cancer patients. J Antimicrob Chemother 1998;41 (suppl D):65-80.